MDR-reversal activity of chalcones

Area of Science:

• Medicinal Chemistry
• Cancer Biology
• Pharmacology

Background:

• Multidrug resistance (MDR) in cancer hinders chemotherapy efficacy.
• P-glycoprotein (P-gp) is a key efflux pump responsible for MDR.
• Chalcones are a class of compounds with potential therapeutic applications.

Purpose of the Study:

• To investigate the ability of 11 chalcone derivatives to inhibit P-glycoprotein.
• To evaluate the reversal of multidrug resistance by these chalcones.
• To assess the antiproliferative effects of the tested chalcones.

Main Methods:

• Flow cytometry was used to measure rhodamine-123 accumulation in multidrug-resistant cells.
• The MTT assay was employed to determine antiproliferative activity (ID50 values).
• Verapamil served as a positive control for P-gp inhibition.

Main Results:

• Most chalcones effectively inhibited P-glycoprotein-mediated efflux of rhodamine-123.
• Chalcones 2, 3, 5, and 7 demonstrated potent antiproliferative effects (ID50 < 0.3 microg/mL).
• Chalcone 7, with a p-chloro substitution, was most effective in MDR reversal and showed synergistic effects with epirubicin.

Conclusions:

• Chalcone derivatives are effective inhibitors of P-glycoprotein.
• Specific chalcone structures, particularly with p-chloro substitution, show significant potential for MDR reversal.
• These findings suggest chalcones as promising candidates for overcoming multidrug resistance in cancer therapy.